Prospective Study of Rituximab in Chemotherapy-Dependent Human Immunodeficiency Virus–Associated Multicentric Castleman's Disease: ANRS 117 CastlemaB Trial | Synapse
July 30, 2007Open Access
Prospective Study of Rituximab in Chemotherapy-Dependent Human Immunodeficiency Virus–Associated Multicentric Castleman's Disease: ANRS 117 CastlemaB Trial
Key Points
Key points are not available for this paper at this time.
Abstract
Rituximab was both effective and safe in HIV-infected patients with chemotherapy-dependent MCD.